Hiromi Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiromi Tanaka has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- David Gilley
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202
2 shared publications Brenda Grimes
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202
1 shared publication- Chikako Ishihara
Research and Development Headquarters, Lion Corporation, 7-2-1 Hirai, Edogawa-ku, Tokyo, 132-0035, Japan.
1 shared publication - Dong-Lai Qi
Department of Biomedical Science, Graduate School of Medical Science, and Chromosome Engineering Research Center, Tottori University, 86 Nishicho, Yonago 683-8503, Japan
1 shared publication - Hiroyuki Kugoh
Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago, Tottori, 683-8503, Japan.
1 shared publication Izumi Horikawa
Laboratory of Biosystems and Cancer, Cancer and Aging Section, Center for Cancer Research, NCI/NIH, Bethesda, MD, USA
1 shared publication
Latest Publications
- 13 August 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (35) , 14098-14103
Telomere fusions in early human breast carcinoma
Several lines of evidence suggest that defects in telomere maintenance play a significant role in the initiation of genomic instability during carcinogenesis. Although the general concept of defective telomere maintenance initiating genomic instability has been acknowledged, there remains a critical gap in the direct evidence of telomere dysfunction in human solid tumors. To address this topic, we devised a multiplex PCR-based assay, termed TAR (telomere-associated repeat) fusion PCR, to detect and analyze chromosome end-to-end associations (telomere fusions) within human breast tumor tissue. Using TAR fusion PCR, we found that human breast lesions, but not normal breast tissues from healthy volunteers, contained telomere fusions. Telomere fusions were detected at similar frequencies during early ductal carcinoma in situ and in the later invasive ductal carcinoma stage. Our results provide direct evidence that telomere fusions are present in human breast tumor tissue and suggest that telomere dysfunction may be an important component of the genomic instability observed in this cancer. Development of this robust method that allows identification of these genetic aberrations (telomere fusions) is anticipated to be a valuable tool for dissecting mechanisms of telomere dysfunction.
- 13 August 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (35) , 14098-14103
Telomere fusions in early human breast carcinoma
Several lines of evidence suggest that defects in telomere maintenance play a significant role in the initiation of genomic instability during carcinogenesis. Although the general concept of defective telomere maintenance initiating genomic instability has been acknowledged, there remains a critical gap in the direct evidence of telomere dysfunction in human solid tumors. To address this topic, we devised a multiplex PCR-based assay, termed TAR (telomere-associated repeat) fusion PCR, to detect and analyze chromosome end-to-end associations (telomere fusions) within human breast tumor tissue. Using TAR fusion PCR, we found that human breast lesions, but not normal breast tissues from healthy volunteers, contained telomere fusions. Telomere fusions were detected at similar frequencies during early ductal carcinoma in situ and in the later invasive ductal carcinoma stage. Our results provide direct evidence that telomere fusions are present in human breast tumor tissue and suggest that telomere dysfunction may be an important component of the genomic instability observed in this cancer. Development of this robust method that allows identification of these genetic aberrations (telomere fusions) is anticipated to be a valuable tool for dissecting mechanisms of telomere dysfunction.
- Open Access
- 26 May 2010
- Published by ScienceOpen in Genome Integrity
- Vol. 1 (1) , 6
Localization of an hTERT repressor region on human chromosome 3p21.3 using chromosome engineering
Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric DNA. The reactivation of telomerase activity by aberrant upregulation/expression of its catalytic subunit hTERT is a major pathway in human tumorigenesis. However, regulatory mechanisms that control hTERT expression are largely unknown. Previously, we and others have demonstrated that the introduction of human chromosome 3, via microcell-mediated chromosome transfer (MMCT), repressed transcription of the hTERT gene. These results suggested that human chromosome 3 contains a regulatory factor(s) involved in the repression of hTERT. To further localize this putative hTERT repressor(s), we have developed a unique experimental approach by introducing various truncated chromosome 3 regions produced by a novel chromosomal engineering technology into the renal cell carcinoma cell line (RCC23 cells). These cells autonomously express ectopic hTERT (exohTERT) promoted by a retroviral LTR promoter in order to permit cellular division after repression of endogenous hTERT. We found a telomerase repressor region located within a 7-Mb interval on chromosome 3p21.3. These results provide important information regarding hTERT regulation and a unique method to identify hTERT repressor elements.
- 26 May 2010
- Published by ScienceOpen in Genome Integrity
- Vol. 1 (1) , 6
Open AccessLocalization of an hTERT repressor region on human chromosome 3p21.3 using chromosome engineering
Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric DNA. The reactivation of telomerase activity by aberrant upregulation/expression of its catalytic subunit hTERT is a major pathway in human tumorigenesis. However, regulatory mechanisms that control hTERT expression are largely unknown. Previously, we and others have demonstrated that the introduction of human chromosome 3, via microcell-mediated chromosome transfer (MMCT), repressed transcription of the hTERT gene. These results suggested that human chromosome 3 contains a regulatory factor(s) involved in the repression of hTERT. To further localize this putative hTERT repressor(s), we have developed a unique experimental approach by introducing various truncated chromosome 3 regions produced by a novel chromosomal engineering technology into the renal cell carcinoma cell line (RCC23 cells). These cells autonomously express ectopic hTERT (exohTERT) promoted by a retroviral LTR promoter in order to permit cellular division after repression of endogenous hTERT. We found a telomerase repressor region located within a 7-Mb interval on chromosome 3p21.3. These results provide important information regarding hTERT regulation and a unique method to identify hTERT repressor elements.
- Open Access
- 18 April 2005
- Published by Wiley in International Journal of Cancer
- Vol. 115 (4) , 653-657
Evidence for inactivation of distinct telomerase repressor genes in different types of human cancers
Telomerase activation, a critical event in human carcinogenesis, may result from defects in telomerase‐repressing mechanisms. Data from microcell‐mediated chromosome transfer (MMCT) suggests the presence of telomerase repressor genes that become inactivated during carcinogenic processes. The transfer of a normal human chromosome 3 represses telomerase activity of both human renal cell carcinoma (RCC) and breast carcinoma (BC) cells. For a genetic complementation analysis of telomerase repression, 2 RCC cell lines (KC12 and RCC23) and a BC cell line (21NT) were used to make somatic cell hybrids. All of the self‐hybrids (KC12×KC12 and 21NT×21NT) and hybrids from 2 RCC cell lines (KC12×RCC23) expressed the telomerase activity similarly to their parental cells, excluding the possibility of a ploidy‐associated change in telomerase activity and suggesting the same genetic defect shared by the 2 RCC cell lines. In contrast, the fusion of BC and RCC cells (21NT×KC12 and 21NT×RCC23) produced a significant number of telomerase‐negative hybrids, suggesting that the RCC and BC cells have different defects in the telomerase repression, which are functionally corrected through genetic complementation in the hybrids. This notion was supported by the mapping of the RCC telomerase repressor gene to a 5.7‐Mb region on 3p21, which is different from the candidate region for the BC telomerase repressor gene on the same chromosomal band. These findings provide direct evidence for inactivation of distinct telomerase repressor genes in different types of human cancers and may have implications in the tissue‐specific regulation of telomerase during human development and carcinogenesis.
- 18 April 2005
- Published by Wiley in International Journal of Cancer
- Vol. 115 (4) , 653-657
Open AccessEvidence for inactivation of distinct telomerase repressor genes in different types of human cancers
Telomerase activation, a critical event in human carcinogenesis, may result from defects in telomerase‐repressing mechanisms. Data from microcell‐mediated chromosome transfer (MMCT) suggests the presence of telomerase repressor genes that become inactivated during carcinogenic processes. The transfer of a normal human chromosome 3 represses telomerase activity of both human renal cell carcinoma (RCC) and breast carcinoma (BC) cells. For a genetic complementation analysis of telomerase repression, 2 RCC cell lines (KC12 and RCC23) and a BC cell line (21NT) were used to make somatic cell hybrids. All of the self‐hybrids (KC12×KC12 and 21NT×21NT) and hybrids from 2 RCC cell lines (KC12×RCC23) expressed the telomerase activity similarly to their parental cells, excluding the possibility of a ploidy‐associated change in telomerase activity and suggesting the same genetic defect shared by the 2 RCC cell lines. In contrast, the fusion of BC and RCC cells (21NT×KC12 and 21NT×RCC23) produced a significant number of telomerase‐negative hybrids, suggesting that the RCC and BC cells have different defects in the telomerase repression, which are functionally corrected through genetic complementation in the hybrids. This notion was supported by the mapping of the RCC telomerase repressor gene to a 5.7‐Mb region on 3p21, which is different from the candidate region for the BC telomerase repressor gene on the same chromosomal band. These findings provide direct evidence for inactivation of distinct telomerase repressor genes in different types of human cancers and may have implications in the tissue‐specific regulation of telomerase during human development and carcinogenesis.